PACIFIC BIOSCIENCES of CALIF

Mark Van Oene’s August sell‑off is routine tax‑withholding, but his bulk option buys show insider confidence in PACB’s SMRT tech and future upside.

Van Oene Mark’s massive insider buys at Pacific Biosciences signal strong confidence, offering investors a counterpoint to the stock’s recent volatility and a look into long‑term upside.

Insider option buys at Pacific Biosciences signal bullish confidence, spurring a 10.88% weekly gain and hinting at future price growth driven by SMRT sequencing technology.